NERLYNX (neratinib)
SELF ADMINISTRATION
Indications for Prior Authorization:
- Kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2) over expressed/amplified breast cancer, to follow adjuvant Herceptin (trastuzumab infusion) based therapy
This medication is not approvable for the following condition(s):
- Concurrent use of Nerlynx with other medications for adjuvant or neoadjuvant treatment of HER2-positive breast cancer
All of the following must be met as a condition for coverage:
- Prescribed by an oncologist, AND
- Patient has early-stage disease, AND
- Women with HER2-positive breast cancer, AND
- Completed 1 year of therapy with Herceptin, OR
- Tried and intolerant to 1 year therapy with Herceptin
Dosing:
- Recommended dose: 240 mg (6 tablets) orally once daily for 1 year
- Hepatic Impairment (Child Pugh C): 80 mg (2 tablets) once daily
Approval:
- One year
Last review date: September 4, 2018